Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Bilateral Superselective Adrenal Arterial Embolization (BiSAAE) for Resistant Hypertension

NCT06282107 is registered in ClinicalTrials.gov with First Affiliated Hospital of Chengdu Medical College as lead sponsor.

NCT NCT06282107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Bilateral Superselective Adrenal Arterial Embolization (BiSAAE) for Resistant Hypertension
Lead sponsor
First Affiliated Hospital of Chengdu Medical College
Phase
Not applicable
Overall status
Not yet recruiting
Start date
January 1, 2025
Completion date
December 31, 2026
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

resistant hypertension